Ibrutinib Bests Chlorambucil in Elderly Patients with Treatment-Naïve CLL/SLL
Paul Barr, MD, discusses the results of the RESONATE-2, which evaluates efficacy of the Bruton’s tyrosine kinase inhibitor, ibrutinib versus chlorambucil in patients who are 65 years old or older with chronic lymphocytic leukemia or small lymphocytic lymphoma.
Paul Barr, MD, a hematologist oncologist at the University of Rochester Medical Center, discusses the results of the RESONATE-2 (NCT01722487), which evaluates efficacy of the Bruton’s tyrosine kinase inhibitor, ibrutinib versus chlorambucil in patients who are 65 years old or older with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
According to Barr, ibrutinib continues to show superior overall survival and progression-free survival (PFS) over chlorambucil. At 6.5 years, the PFS for the ibrutinib group was 61%. A similar benefit was also seen in patients who had high-risk disease, including those who were IGHV-unmutated.
In terms of response rate, the rate of complete remission (CR) with ibrutinib continues to rise, according to Barr. The CR rate is at 34%. Additionally, no new safety signals were noted.
Oncologists Discuss a Second-Generation BTK for Relapsed/Refractory CLL
December 18th 2024During a Case-Based Roundtable® event, Daniel A. Ermann, MD, discussed evaluation and treatment for a patient with relapsed chronic lymphocytic leukemia after receiving venetoclax and obinutuzumab.
Read More
